The metastasis-associated protein MTA3 promotes cardiac repair by inhibiting the fibroblast to myofibroblast transition during fibrosis
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Xu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China; The State Key Laboratory of Frigid Zone Cardiovascular Dis…. Hauptthemen laut MEDLINE: Myofibroblasts, Fibroblasts, Myocardium, Myocardial Infarction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiac fibrosis is a pathological hallmark of various cardiovascular disorders. Accumulating evidence has demonstrated that fibroblasts transform into myofibroblasts during the occurrence of cardiac fibrosis, but the mechanism remains incompletely understood. This study aims to investigate the relevance of MTA3 as a potential therapeutic target for cardiac fibrosis. The myocardial infarction model was established by ligating the left coronary artery of C57BL6 mice, and myocardial fibrosis was measured by cardiac ultrasound and Sirius red staining of myocardium. MTA3 overexpression plasmid was constructed and transfected into primary fibroblasts, immunofluorescence, Western blot and qRT-PCR were used to detect the expression of MTA3, α-SMA, and Collagen I. RNAi was used to interfere with the downstream potential target gene E2F1. SB203580, a specific inhibitor of p38 MAPK, reduced the levels of phosphorylated p38 MAPK (p-p38) by inhibiting p38 MAPK activity, and allowed assessment of MTA3-induced fibroblast to myofibroblast transformation. The expression of MTA3 was reduced in fibrotic myocardium. Overexpression of MTA3 could restore cardiac function. During the transformation process of cardiac fibroblasts into myofibroblasts, the expression of MTA3 was downregulated. After overexpression of MTA3, the mRNA and protein levels of α-SMA and Collagen I were significantly reduced. When E2F1 was disrupted, the mRNA and protein levels of α-SMA and Collagen I were downregulated. Inhibition of p-p38 MAPK expression by SB203580 ameliorated myocardial fibrosis. MTA3 regulates the transformation of fibroblast into myofibroblast by p38 MAPK-E2F1 signaling pathway, and MTA3 may become a potential target for treating cardiac fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China; The State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), and the Key Laboratory of Cardiovascular Medicine Res…
- The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
- Heilongjiang Nursing College, Harbin, Heilongjiang, China.
- Zhengzhou Research Institute, Harbin Institute of Technology, Zhengzhou, Henan, China.
Zitieren
APA
Wang, X., Liu, Y., Liu, H., Zhang, M., Yang, L., Dinislam, K., Hu, H., Xiao, D., Yang, H., & Zhang, Y. (2025). The metastasis-associated protein MTA3 promotes cardiac repair by inhibiting the fibroblast to myofibroblast transition during fibrosis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110448
Vancouver
Wang X, Liu Y, Liu H, Zhang M, Yang L, Dinislam K, et al. The metastasis-associated protein MTA3 promotes cardiac repair by inhibiting the fibroblast to myofibroblast transition during fibrosis. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110448
BibTeX
@article{Wang2025,
author = {Wang, Xu and Liu, Yihui and Liu, Heng and Zhang, Mengfan and Yang, Lida and Dinislam, Khuzin and Hu, Hongbo and Xiao, Dan and Yang, Huan and Zhang, Ying},
title = {The metastasis-associated protein MTA3 promotes cardiac repair by inhibiting the fibroblast to myofibroblast transition during fibrosis},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110448}
}
EUVIMED